A RANDOMIZED DOUBLE-BLIND TREATMENT STRATEGY STUDY EVALUATING CONTINUATION OR REDUCED-FREQUENCY DOSING OF CERTOLIZUMAB PEGOL VERSUS WITHDRAWAL TO MAINTAIN LOW DISEASE ACTIVITY IN EARLY RA PATIENTS (C-EARLY PERIOD 2)

被引：1

作者：

Emery, P. ^{[1
]}

Bingham, C. ^{[2
]}

Burmester, G. -R. ^{[3
]}

Bykerk, V. P. ^{[4
]}

Furst, D. ^{[5
]}

Mariette, X. ^{[6
]}

van der Heijde, D. ^{[7
]}

van Vollenhoven, R. ^{[8
]}

VanLunen, B. ^{[9
]}

Ecoffet, C. ^{[10
]}

Cioffi, C. ^{[9
]}

Weinblatt, M. ^{[11
]}

机构：

[1] Univ Leeds, Leeds, W Yorkshire, England

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Charite, Berlin, Germany

[4] Weill Cornell Coll, New York, NY USA

[5] Univ Calif Los Angeles, Los Angeles, CA USA

[6] Univ Paris Sud, Paris, France

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands

[9] UCB Pharma, Raleigh, NC USA

[10] UCB Pharma, Brussels, Belgium

[11] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2016-eular.1468

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

OP0227

引用

页码：143 / 144

页数：2